E
Rapid Dose Therapeutics Corp.
DOSE
CNSX
E
Sell
8/15/2024Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 8/15/2024 due to a noticeable decline in the solvency index and valuation index. The quick ratio declined from 0.13 to 0.12.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 8/15/2024 due to a noticeable decline in the solvency index and valuation index. The quick ratio declined from 0.13 to 0.12.
D
Sell
6/28/2023Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E+ on 6/28/2023 due to a noticeable increase in the volatility index and total return index.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E+ on 6/28/2023 due to a noticeable increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E+ on 02/23/2023.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index and total return index. Debt to equity increased from -1.74 to -1.34.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index and total return index. Debt to equity increased from -1.74 to -1.34.
D
Sell
1/30/2023Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to D- from D on 1/30/2023 due to a significant decline in the solvency index, growth index and total return index. Operating cash flow declined 111.21% from -$92.8 to -$196, total revenue declined 92.63% from $659.5 to $48.6, and the quick ratio declined from 0.09 to 0.05.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to D- from D on 1/30/2023 due to a significant decline in the solvency index, growth index and total return index. Operating cash flow declined 111.21% from -$92.8 to -$196, total revenue declined 92.63% from $659.5 to $48.6, and the quick ratio declined from 0.09 to 0.05.
D
Sell
5/16/2022Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index, volatility index and valuation index.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index, volatility index and valuation index.
E
Sell
5/13/2022Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
E
Sell
5/1/2022Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
E
Sell
4/20/2022Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the volatility index and total return index.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the volatility index and total return index.
D
Sell
11/9/2021Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 11/09/2021.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index and growth index. Earnings per share declined from $0.0013 to -$0.0049.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index and growth index. Earnings per share declined from $0.0013 to -$0.0049.
D
Sell
11/18/2020Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from D- on 11/18/2020 due to a major increase in the growth index, valuation index and total return index. Total revenue increased 92.86% from $1.4 to $2.7.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D from D- on 11/18/2020 due to a major increase in the growth index, valuation index and total return index. Total revenue increased 92.86% from $1.4 to $2.7.
D
Sell
10/14/2020Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E+ on 10/14/2020 due to an increase in the volatility index and total return index.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E+ on 10/14/2020 due to an increase in the volatility index and total return index.
E
Sell
11/15/2019Downgrade
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 11/15/2019 due to a decline in the efficiency index, solvency index and total return index. The quick ratio declined from 1.4 to 0.76, and total capital declined 13.91% from $2.23M to $1.92M.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E+ from D- on 11/15/2019 due to a decline in the efficiency index, solvency index and total return index. The quick ratio declined from 1.4 to 0.76, and total capital declined 13.91% from $2.23M to $1.92M.
D
Sell
9/3/2019Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E on 9/3/2019 due to a large increase in the solvency index, efficiency index and growth index. Total revenue increased 811.76% from -$1.7 to $12.1, net income increased 68.16% from -$7.2M to -$2.29M, and earnings per share increased from -$0.0821 to -$0.0305.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to D- from E on 9/3/2019 due to a large increase in the solvency index, efficiency index and growth index. Total revenue increased 811.76% from -$1.7 to $12.1, net income increased 68.16% from -$7.2M to -$2.29M, and earnings per share increased from -$0.0821 to -$0.0305.
E
Sell
6/3/2019Upgraded
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to E from E- on 6/3/2019 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 36.48% from -$552.9 to -$351.2.
Rapid Dose Therapeutics Corp. (DOSE) was upgraded to E from E- on 6/3/2019 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 36.48% from -$552.9 to -$351.2.
E
Sell
3/13/2019None
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E- from U on 03/13/2019.
Rapid Dose Therapeutics Corp. (DOSE) was downgraded to E- from U on 03/13/2019.
